SQUAWK/NEWS
Account
Theme
Account
Menu
Live News MNA ARTICLE H impact

Novo Nordisk licenses Hengrui oral GLP-1/GIP drug HRS-1596

Novo Nordisk will pay $300M upfront for exclusive rights to HRS-1596 outside mainland China, Hong Kong, Macao and Taiwan, in a deal valued up to $2.6B. The phase 1-ready dual GLP-1/GIP agonist targets weight management and type 2 diabetes, with potential once-weekly oral dosing. Additional milestone and sales payments are included, and closing is expected in Q4 2026, subject to U.S. antitrust clearance and customary conditions.

Novo Nordisk said it has licensed Hengrui’s oral GLP-1/GIP drug HRS-1596 in a deal valued at up to $2.6B. The company will pay $300M upfront for exclusive rights outside mainland China, Hong Kong, Macao and Taiwan. HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist in development for weight management and type 2 diabetes, with potential once-weekly oral dosing. The deal also includes additional milestone and sales-related payments.

Closing is expected in Q4 2026, subject to U.S. antitrust clearance and customary conditions.

Related stories